Brigatinib in Crizotinib-Refractory ALK plus NSCLC : Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial
2017
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI